The radon app
BehavioralParticipants will be asked to use the radon app.
NCT Number: NCT07591389
Radon is the second-leading cause of lung cancer after smoking and may contribute to other cancer deaths; children are especially vulnerable due to a larger lung surface area and higher respiratory rates. The goal of this research is to test the feasibility of the radon app to promote radon testing among mothers of children aged 4 or younger when they receive a free radon test kit.
Interested in participating?
Request Info18 year and older
Female
Interventional
Not applicable
University of North Dakota Center for Family Medicine, Bismarck Clinic, Bismarck, North Dakota, United States
This feasibility study enrolls mothers of children under age 4 who receive a free short-term radon test kit. Participants are introduced to and given access to a smartphone radon app designed to deliver targeted education, step-by-step testing instructions, reminders, and social-sharing prompts. The study measures cognitive outcomes (radon knowledge, self-efficacy for testing, and response efficacy beliefs) before and after app exposure, and behavioral outcomes (whether the test kit is completed and returned for lab analysis, and whether participants share radon information or recommend testing to others). Data collection combines brief baseline and follow-up surveys, app usage analytics (e.g., time in app, modules completed, reminder interactions), and laboratory confirmation of returned kits. Feasibility metrics include recruitment and retention rates, app engagement, and kit return rates.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will be asked to use the radon app.
Time frame: Initial Enrollment to 2 months after enrollment
T1 (baseline: pre-exposure survey, distribution of free radon test kit). The pre-expsosure survey will measure: Primary endpoints: (1) Radon knowledge, 20 true/false items); (2) self-efficacy, response efficacy, and sharing intention (7-point Likert).
Time frame: 2 months after enrollment
T2 refers to the time point where participants will complete the post-exposure survey, which will happen two months after T1. The primary endpoints are: (1) Changes in radon knowledge from T1 to T2, as measured by the number of correct responses to a series of 20 true/false questions (e.g., "The EPA recommends that homes with 4 picocuries per liter (pCi/L) or more of radon should be fixed."); (2) Changes in self-efficacy, response efficacy, and sharing intention from T1 to T2, measured by 7-point Likert scales; (3) Radon information shared with others and recommended to others to test their houses for radon from T1 to T2. It will be measured by a series of yes/no questions. Analyses: Aim 1-directional dependent t-tests for mean changes; McNemar's test for paired proportions of sharing.
Time frame: 4 months after last enrollment
Number of radon test kits used and returned to the laboratory by participants. Directional McNemar's test for kit return proportions T1 vs T3.
Contact information is provided by the study sponsor or research team.
Soojung Kim Interim Dean, School of Graduate Studies, PhD, MPH
CONTACT
University of North Dakota
Other
Promoting Radon Testing Among Mothers of Young Children: A Translational Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07168993
Disease, Lung Cancer (Diagnosis)
Palo Alto, California, United States
View Trial DetailsNCT07675967
Adenocarcinoma Of Esophagus, Bone Diseases
Boston, Massachusetts, United States
View Trial DetailsNCT07393490
Disease, Lung Cancer (Diagnosis)
Osijek, Croatia
View Trial DetailsNCT07001670
Anxiety Disorders, Behavior
Istanbul, Turkey (Türkiye)
View Trial Details